Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer

BACKGROUND: Previous clinical trials indicated the addition of anti‐PD‐1 antibody remarkably improved the efficacy of trastuzumab and chemotherapy in patients with HER2‐positive gastric/gastroesophageal junction (GEJ) cancer. However, no real‐world experiences have been reported yet. METHODS: We ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ju, Shi, Zhan, Zhang, Xin, Liu, Qin, Cui, Xiaobin, Li, Lin, Liu, Baorui, Wei, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166915/
https://www.ncbi.nlm.nih.gov/pubmed/36912199
http://dx.doi.org/10.1002/cam4.5722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166915/
https://www.ncbi.nlm.nih.gov/pubmed/36912199
http://dx.doi.org/10.1002/cam4.5722

Ejemplares similares